Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961352 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL1487007 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL765807 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL8520973 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345859 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL11961353 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345858 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL3974543 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL16730247 | 0.84 | CA2 (0.32) | CA2 | |
| SCHEMBL3016063 | 0.84 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518561-B | Silicon etchant and application thereof | 才将科技股份有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-111518561-A | Silicon etchant and application thereof | 才将科技股份有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-2460842-A2 | Novel energetic polyphosphazenes | The Secretary of State For Defence (GB) | 2012-06-06 | — | — | EP | claimed |
| EP-1960456-A1 | NOVEL ENERGETIC POLYPHOSPHAZENES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2008-08-27 | — | — | EP | claimed |
| WO-2006032882-A1 | NOVEL ENERGETIC POLYPHOSPHAZENES | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2006-03-30 | — | — | WO | claimed |
| EP-4705570-A1 | WOOD DIGESTION PROCESS | Technikum Laubholz GmbH (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4263492-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024227791-A1 | WOOD DIGESTION PROCESS | TECHNIKUM LAUBHOLZ GMBH (DE) | 2024-11-07 | — | — | WO | disclosed |
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. | 2024-04-25 | — | — | US | disclosed |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| CN-111417712-B | Liquid detergent product for fiber products | 狮王株式会社 | 2022-09-30 | — | — | CN | disclosed |
| CN-111433337-A | Perfume composition | 狮王株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| US-5102895-A | Antilipemic agent having a number of nicotinic acid molecule bonded to vitamin; synergistic, side effect reduction | EISAI CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0436911-A2 | Novel vitamin E derivatives and process for the production thereof | Eisai Co., Ltd. (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0250358-A2 | Novel complex compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132450-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR65, GPR68 | L3MBTL1 3949/4885CA2 4832/4885 |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | ETV6, PKD1, PKD2 | L3MBTL1 3765/4885CA2 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.